This study showed that the combination of anti-PD-L1 antibody atezolizumab with the A2AR antagonist ciforadenant increased recruitment of cytotoxic T cells to tumor regions, and increased the diversity of T-cell receptors, which together prolonged overall survival of patients [159]. Here, ADORA2A is linked to neoplasm.